

**NOTICE OF INTENT TO AMEND RULE IN THE GEORGIA STATE BOARD OF  
PHARMACY RULES,  
RULE 480-34-.04 SYNTHETIC CANNABINOIDS., AND NOTICE OF PUBLIC HEARING**

TO ALL INTERESTED PERSONS AND PARTIES:

Notice is hereby given that pursuant to the authority set forth below, the Georgia State Board of Pharmacy (hereinafter "Board") proposes amendments to the Georgia Board of Pharmacy Rules, Rule 480-34-.04 SYNTHETIC CANNABINOIDS. (hereinafter "proposed amendments").

This notice, together with an exact copy of the proposed amendments and a synopsis of the proposed amendments, is being forwarded to all persons who have requested, in writing, that they be placed on an interested parties list. A copy of this notice, an exact copy of the rule including the proposed amendments, and a synopsis of the rule including the proposed amendments may be reviewed during normal business hours of 8:00 a.m. to 5:00 p.m. Monday through Friday, except official State holidays, at the Department of Community Health at 2 Peachtree Street NW, Atlanta, Georgia, 30303. These documents will also be available for review on the Georgia State Board of Pharmacy's web page at [www.gbp.georgia.gov](http://www.gbp.georgia.gov).

A public hearing is scheduled to begin at 11:00 AM on January 14, 2016 at the South University School of Pharmacy, 709 Mall Boulevard, Savannah, Georgia 31406 to provide the public an opportunity to comment upon and provide input into the proposed amendments. At the public hearing, anyone may present data, make a statement, comment or offer a viewpoint or argument whether orally or in writing. Lengthy statements or statements of a considerable technical or economic nature, as well as previously recorded messages, must be submitted for the official record. Oral statements should be concise and will be limited to 5 minutes per person. Additional comments should be presented in writing. Written comments are welcome. To ensure their consideration, written comments must be received prior to January 4, 2016. Written comments should be addressed to the Executive Director of the Georgia State Board of Pharmacy at 2 Peachtree Street NW, Atlanta, Georgia 30303 FAX: 678-717-6435. You may email your comments to [tbattle@dch.ga.gov](mailto:tbattle@dch.ga.gov).

The proposed amendments will be considered for adoption by the Georgia State Board of Pharmacy at its meeting scheduled to begin at 11:05 AM on 1/14/2016 at the South University School of Pharmacy, 709 Mall Boulevard, Savannah, Georgia 31406. According to the Department of Law, State of Georgia, the Georgia State Board of Pharmacy has the authority to adopt the proposed amendments pursuant to authority contained in O.C.G.A. §§ 16-13-22, 26-4-28, and 50-13-4.


At its meeting on October 8, 2015, the Board voted that the formulation and adoption of these rule amendments do not impose excessive regulatory cost on any licensee and any cost to comply with the proposed amendments cannot be reduced by a less expensive alternative that fully accomplishes the objectives of O.C.G.A §§ 26-4-27, 26-4-28, 16-13-22.

At its meeting on 10/8/2015, the Board also voted that it is not legal or feasible to meet the objectives of O.C.G.A §§ 26-4-27, 26-4-28, 16-13-22 to adopt or implement differing actions for businesses as listed at O.C.G.A § 50-13-4(a)(3)(A), (B), (C) and (D). The formulation and adoption of these amendments will impact every licensee in the same manner, and each licensee is independently licensed, owned and operated and dominant in the field of pharmacy.

For further information, contact the Board office at 404-651-8000.

This notice is given in compliance with O.C.G.A. §50-13-4.

This 30th day of November, 2015.

Handwritten signature of Tanja D. Battle in black ink.

---

Tanja D. Battle  
Executive Director  
Georgia Board of Pharmacy

Posted: November 30, 2015

**SYNOPSIS OF PROPOSED AMENDMENTS TO THE  
GEORGIA STATE BOARD OF PHARMACY RULE  
480-34-.04 SYNTHETIC CANNABINOIDS.**

Purpose of Amendments: The purpose of these amendments is to protect the health, safety, and welfare of the public.

Main Features: The main feature of these amendments is to add additional substances to Schedule I of the Georgia Controlled Substances Act.

**DIFFERENCES OF THE PROPOSED AMENDMENTS TO THE  
GEORGIA STATE BOARD OF PHARMACY RULE  
480-34-.04 SYNTHETIC CANNABINOIDS.**

NOTE: Struck through text is proposed to be deleted. Underlined text is proposed to be added.

**480-34-.04 Synthetic Cannabinoids.**

(1) This rule was adopted to protect the health, safety, and welfare of the public. This rule places newly identified compounds, including any material, compound, mixture, or preparation which contains these substances or their derivatives, salts, isomers, or salts of isomers, halogen analogues, and/or homologues, collectively known as Synthetic Cannabinoids, under Schedule I, of the Georgia Controlled Substances Act, Code Section 16-13-25 (12) as follows:

- (M) (1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl) methanone (UR-144)
- (N) [1-(5-fluoropentyl)indole-3-yl]-(2,2,3,3-tetramethylcyclopropyl) methanone (XLR11)
- (O) [1,1'-biphenyl]-3-yl-carbamic acid, cyclohexyl ester (URB602)
- (P) [1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl) methanone (A-796,260)
- (Q) [3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate (URB597).
- (R) 6-methyl-2-[(4-methylphenyl)amino]-1-benzoxazin-4-one (URB754)
- (S) 1-pentyl-N-tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-yl-1H-indazole-3-carboxamide (AKB48)
- (T) 1-pentyl-3-(1-adamantylamido)indole (2NE1)
- (U) 1-(5-fluoropentyl)-N-tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-yl-1H-indole-3-carboxamide (STS-135)
- (V) 1-naphthalenyl[4-(pentyl)-1-naphthalenyl]-methanone (CB-13)
- (W) (1-(5-chloropentyl)indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (5-Chloro-UR-144)
- (X) (1-(5-bromopentyl)indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (5-Bromo-UR-144)
- (Y) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide (ADBICA)
- (Z) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5-Fluoro-ADBICA)
- (aa) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5fluoro-ABICA)
- (bb) (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (FUB-144)
- ~~(cc) Naphthalene-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (NM2201)~~
- (cc) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5-fluoro-ABICA);
- (dd) 1-naphthalenyl(1-pentyl-1H-indazol-3-yl)-methanone (THJ 018);
- (ee) 1-(cyclohexylmethyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid (BB-22);

(ff) Naphthalene-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (NM2201).

(2) This rule is based on the following findings of the Board:

(a) that Synthetic Cannabinoids have an extremely high potential for abuse;

(b) that scientific evidence and scientific knowledge of the pharmacological effects of these compounds demonstrate that the public is at extreme risk if they are not regulated as controlled substances;

(c) that the pattern of abuse of these compounds and the scope and significance of that abuse support regulation;

(d) that there exists an imminent peril to the public health and welfare with regard to the abuse of these compounds;

(e) that these compounds have the same risk to the public health of citizens of the State of Georgia as other substances already contained in Schedule I under the Controlled Substances Act;

(f) that these compounds have no known precursor already scheduled under the Act; and

(g) that the DEA encourages all states to add these compounds to their respective Controlled Substances Acts while DEA follows its procedures to add such compounds to the Federal Controlled Substances Act under Schedule I.

Authority: O.C.G.A §§ 16-13-22, 26-4-28, and 50-13-4.